Genprex, Inc. Files 8-K: Other Events & Financials
Ticker: GNPX · Form: 8-K · Filed: Nov 20, 2024 · CIK: 1595248
Sentiment: neutral
Topics: 8-K, financials, corporate-events
Related Tickers: GNPX
TL;DR
Genprex filed an 8-K on Nov 20, 2024, covering other events and financials. Stay tuned for details.
AI Summary
Genprex, Inc. filed an 8-K on November 20, 2024, reporting other events and financial statements. The company, incorporated in Delaware with its principal executive offices in Austin, Texas, operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing provides an update on Genprex's corporate activities and financial status, which is crucial for investors to assess the company's ongoing operations and performance.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, which typically reports significant events or financial updates without immediate, drastic implications.
Key Numbers
- 001-38244 — Commission File Number (Identifier for the company's SEC filings)
- 90-0772347 — I.R.S. Employer Identification Number (Tax identification number for the company)
Key Players & Entities
- Genprex, Inc. (company) — Registrant
- November 20, 2024 (date) — Date of report
- Austin, Texas (location) — Principal executive offices location
- Delaware (location) — State of incorporation
- Pharmaceutical Preparations (industry) — Standard Industrial Classification
FAQ
What specific 'Other Events' are being reported in this 8-K filing?
The provided text does not detail the specific 'Other Events' covered in the 8-K, only that this item is included.
What is the nature of the 'Financial Statements and Exhibits' being filed?
The filing indicates that 'Financial Statements and Exhibits' are part of this 8-K, but the specific content of these statements is not detailed in the provided text.
When was Genprex, Inc. incorporated?
Genprex, Inc. was incorporated in Delaware.
What is Genprex, Inc.'s primary business sector?
Genprex, Inc.'s primary business sector is Pharmaceutical Preparations, as indicated by its Standard Industrial Classification code [2834].
What is the address of Genprex, Inc.'s principal executive offices?
Genprex, Inc.'s principal executive offices are located at 3300 Bee Cave Road, #650-227, Austin, TX 78746.
Filing Stats: 1,125 words · 5 min read · ~4 pages · Grade level 16.6 · Accepted 2024-11-20 09:29:11
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share GNPX The Nasdaq Capital Ma
Filing Documents
- gnpx20241119_8k.htm (8-K) — 32KB
- 0001437749-24-035812.txt ( ) — 167KB
- gnpx-20241120.xsd (EX-101.SCH) — 3KB
- gnpx-20241120_def.xml (EX-101.DEF) — 12KB
- gnpx-20241120_lab.xml (EX-101.LAB) — 15KB
- gnpx-20241120_pre.xml (EX-101.PRE) — 12KB
- gnpx20241119_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On November 20, 2024, Genprex, Inc. ("Genprex" or the "Company") issued a press release announcing the Company has entered into an exclusive license agreement with the University of Michigan, granting Genprex a worldwide, exclusive license to the University's patent rights relating to Genprex's lead drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), in combination with ALK-inhibitors for the potential treatment of ALK-EML4 positive translocated lung cancer. The Company noted in its press release that REQORSA in combination with ALK-inhibitors could be a potential therapeutic treatment for ALK+ lung cancer. TUSC2 is a tumor suppressor gene that is frequently deleted in lung cancer. Research collaborators at the University of Michigan Rogel Cancer Center's Judith Tam ALK Lung Cancer Research Initiative presented positive preclinical data at the April 2024 American Association for Cancer Research Annual Meeting, reporting that REQORSA induced apoptosis in alectinib resistant EML4-ALK positive non-small cell lung cancer ("NSCLC") cell lines. The study found that the use of REQORSA or a TUSC2-containing plasmid to overexpress TUSC2 in ALK+ NSCLC cell lines was effective in decreasing cell growth and proliferation through the activation of apoptotic pathways. Researchers believe the results of this preclinical work support further clinical study of REQORSA as an anti-ALK NSCLC treatment strategy, and Genprex believes this research suggests that REQORSA may be an effective treatment in patients progressing on ALK inhibitors. Cautionary Language Concerning Forward-Looking Statements
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENPREX, INC. Date: November 20, 2024 By: /s/ Ryan Confer Ryan Confer Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer)